Related Experiment Video

Updated: Jun 13, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway

Grzegorz Korpanty1, Elizabeth Smyth, Laura A Sullivan

  • 1Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland. greg.korpanty@gmail.com

Experimental Biology and Medicine (Maywood, N.J.)
|April 21, 2010
PubMed

Insights

New biologic therapies targeting tumor angiogenesis show promise for improving lung cancer survival. This review summarizes clinical data on anti-angiogenic treatments for lung cancer patients.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Lung cancer remains a leading global cause of mortality.
  • Current chemotherapies offer limited improvement in patient prognosis, with a 5-year survival rate around 15% for all stages.
  • Novel therapeutic strategies are urgently needed for lung cancer treatment.

Purpose of the Study:

  • To review recent clinical data on biologic therapies for lung cancer.
  • To focus on therapies that inhibit tumor angiogenesis.
  • To highlight the most clinically relevant anti-angiogenic treatments for lung cancer.

Main Methods:

  • Literature review of clinical studies.
  • Analysis of recent data on biologic therapies for lung cancer.
  • Focus on agents targeting tumor angiogenesis and growth factor receptors.

Main Results:

  • Biologic therapies inhibiting tumor angiogenesis are under investigation for lung cancer.
  • These therapies represent a promising new avenue for improving patient outcomes.
  • Specific clinically relevant agents are discussed in the review.

Conclusions:

  • Inhibiting tumor angiogenesis is a key strategy in developing new lung cancer therapies.
  • Biologic agents targeting angiogenesis hold potential for enhancing lung cancer treatment efficacy.
  • Further clinical research is essential to establish the role of these therapies in patient care.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis07:52

Implantation of Fibrin Gel on Mouse Lung to Study Lung-specific Angiogenesis

Published on: December 21, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...